Pharma BD Deal Intelligence
Eisai and BMS end their $3.1 billion ADC deal, but Eisai announced it will continue independent development of MORAb-202 as a folate receptor alpha-targeted…
Phase 2 randomized NSCLC adenocarcinoma study of MORAb-202 (farletuzumab ecteribulin) TERMINATED; whyStopped: 'Business objectives have changed.' Last update…
Phase 2 open-label randomized study of farletuzumab ecteribulin vs investigator's choice chemotherapy in platinum-resistant HGS…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS and Eisai entered a global co-development collaboration for MORAb-202, a folate receptor alpha-targeting ADC for advanced solid tumors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Eisai Co., Ltd. (this deal) | 2021 | $3.1B | 45 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2021 deals · Bristol-Myers Squibb Company deals · Oncology deals